CN101674823A - 用于与增强的5-脂氧合酶和/或白三烯活性有关的疾病（例如哮喘）的r-齐留通 - Google Patents

用于与增强的5-脂氧合酶和/或白三烯活性有关的疾病（例如哮喘）的r-齐留通 Download PDF

Info

Publication number
CN101674823A
CN101674823A CN200880004777A CN200880004777A CN101674823A CN 101674823 A CN101674823 A CN 101674823A CN 200880004777 A CN200880004777 A CN 200880004777A CN 200880004777 A CN200880004777 A CN 200880004777A CN 101674823 A CN101674823 A CN 101674823A
Authority
CN
China
Prior art keywords
zileuton
daily dose
disease
syndrome
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880004777A
Other languages
English (en)
Chinese (zh)
Inventor
W·纽曼
A·库玛
L·利伯廷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi USA Inc
Original Assignee
Critical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Therapeutics Inc filed Critical Critical Therapeutics Inc
Publication of CN101674823A publication Critical patent/CN101674823A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN200880004777A 2007-01-05 2008-01-04 用于与增强的5-脂氧合酶和/或白三烯活性有关的疾病（例如哮喘）的r-齐留通 Pending CN101674823A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87927307P 2007-01-05 2007-01-05
US60/879,273 2007-01-05
PCT/US2008/000101 WO2008085875A2 (en) 2007-01-05 2008-01-04 R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma)

Publications (1)

Publication Number Publication Date
CN101674823A true CN101674823A (zh) 2010-03-17

Family

ID=39339861

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880004777A Pending CN101674823A (zh) 2007-01-05 2008-01-04 用于与增强的5-脂氧合酶和/或白三烯活性有关的疾病（例如哮喘）的r-齐留通

Country Status (7)

Country Link
US (1) US20100273868A1 (enExample)
EP (1) EP2114399A2 (enExample)
JP (1) JP2010515682A (enExample)
CN (1) CN101674823A (enExample)
CA (1) CA2674492A1 (enExample)
MX (1) MX2009007247A (enExample)
WO (1) WO2008085875A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101829075A (zh) * 2010-04-27 2010-09-15 中国人民解放军第三军医大学第一附属医院 苦柯胺a和苦柯胺b的用途
CN102274213A (zh) * 2010-06-10 2011-12-14 北京润德康医药技术有限公司 含有r(+)-齐留通的药用组合物
CN102429872A (zh) * 2011-11-25 2012-05-02 舒泰神（北京）生物制药股份有限公司 含齐留通的膜控型缓释微丸及其制备方法
CN116528901A (zh) * 2020-12-01 2023-08-01 瑞沃斯帕有限责任公司 用于治疗慢性阻塞性肺病、哮喘、肺炎、支气管炎、囊性纤维化和肺水肿的方法和组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120232031A1 (en) * 2009-10-19 2012-09-13 Panmira Pharmaceuticals, Llc Injectable formulations for intra-articular or peri-articular administration
US20110269807A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
US20140323446A1 (en) * 2011-08-23 2014-10-30 Cornerstone Therapeutics Inc. Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
GB201118193D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to oranic compounds
GB201118198D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
WO2016062265A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途
CN107847468A (zh) * 2015-05-26 2018-03-27 纪念斯隆·凯特琳癌症中心 铁死亡和谷氨酰胺分解抑制剂及其治疗方法
WO2024044654A2 (en) * 2022-08-23 2024-02-29 University Of Houston System Parenteral compositions of zileuton and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6786794A (en) * 1993-05-10 1994-12-12 Sepracor, Inc. Methods and compositions using optically pure (+)-zileuton
EP2001861A2 (en) * 2006-02-21 2008-12-17 Critical Therapeutics, Inc. New crystal forms and pharmaceutical compositions of (+)-r-zileuton

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101829075A (zh) * 2010-04-27 2010-09-15 中国人民解放军第三军医大学第一附属医院 苦柯胺a和苦柯胺b的用途
CN101829075B (zh) * 2010-04-27 2011-07-20 中国人民解放军第三军医大学第一附属医院 苦柯胺a和苦柯胺b的用途
CN102274213A (zh) * 2010-06-10 2011-12-14 北京润德康医药技术有限公司 含有r(+)-齐留通的药用组合物
CN102429872A (zh) * 2011-11-25 2012-05-02 舒泰神（北京）生物制药股份有限公司 含齐留通的膜控型缓释微丸及其制备方法
CN116528901A (zh) * 2020-12-01 2023-08-01 瑞沃斯帕有限责任公司 用于治疗慢性阻塞性肺病、哮喘、肺炎、支气管炎、囊性纤维化和肺水肿的方法和组合物

Also Published As

Publication number Publication date
WO2008085875A3 (en) 2009-02-26
WO2008085875A2 (en) 2008-07-17
US20100273868A1 (en) 2010-10-28
MX2009007247A (es) 2009-09-18
CA2674492A1 (en) 2008-07-17
EP2114399A2 (en) 2009-11-11
JP2010515682A (ja) 2010-05-13

Similar Documents

Publication Publication Date Title
CN101674823A (zh) 用于与增强的5-脂氧合酶和/或白三烯活性有关的疾病（例如哮喘）的r-齐留通
KR102528435B1 (ko) 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
US9790222B2 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
ES2236189T3 (es) Nueva combinacion de antihistaminicos no sedativos que contienen sustancias que influyen en la accion del leucotrieno, para el tratamiento de la rinitis/conjuntivitis.
RU2384333C2 (ru) Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин
TW202245789A (zh) Irak4降解劑及其用途
JP2011500577A (ja) バルサルタンの医薬製剤
RU2749189C2 (ru) Композиции и способы лечения ксеростомии
US11000527B2 (en) Therapeutic methods and compositions
US20120238577A1 (en) Prostaglandin transporter inhibitors and uses thereof
US8748488B2 (en) Methods and compositions for administration of oxybutynin
RU2685277C1 (ru) Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных
US9062057B2 (en) CCR5 antagonists for treating HIV
CN107613970A (zh) 短效苯基烷基胺钙通道阻滞剂的高水溶性盐及其应用
US20150197536A1 (en) Compounds reducing the production of sorbitol in the eye and methods of using the same
KR20010015650A (ko) 조합 제제로서의 엔도텔린 길항제 및 베타-수용체 차단제
JP4232866B2 (ja) 細胞障害抑制剤
HK1141731A (en) R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma)
US20250177329A1 (en) Gpr120 agonists for the treatment of inflammatory bowel disease
US20230293537A1 (en) Use of acetamide derivative in prevention and treatment of alzheimer's disease
CN107286147B (zh) N-[5-(1,2,4-三唑-1-基)噻唑-2-基]吗啉基酰胺及其医药用途
CN109305979A (zh) 4-二甲基氨基苯甲醛在制备na抑制剂中的应用
CN118164978A (zh) 二氢喹嗪酮羧酸类化合物及其作为trpv4通道抑制剂的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1141731

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100317